Zaburzenia związane z wadliwą syntezą lub wadliwym wydzielaniem lipoprotein zawierających apolipoproteinę B

• Autorzy: Nowicka G.

Warianty tytułu

EN

Disorders associated with disturbances in synthesis and secretion of APO B containing lipoproteins

• Języki publikacji: PL
• Wydawca: -
• Czasopismo: Żywienie Człowieka i Metabolizm
• Rocznik: 1991
• Tom: 18
• Numer: 3
• Opis fizyczny: s.200-207,bibliogr.

Twórcy

autor

Nowicka G.

• Zakład Żywienia Klinicznego, Instytut Żywności i Żywienia w Warszawie, Warszawa

Bibliografia

• 1. Armstrong V. W., Eberle E., Cremer P.: The association between serum Lp(a) concentrations and angiographically assessed coronary atherosclerosis. Atherosclerosis 1986, 62, 249.
• 2. Armstrong V. W., Walli A. U., Seidel D.: Isolation, characterization and uptake in human fibroblast of an apo(a) — free apoprotein obtained on reduction of lipoprotein(a). J. Lipid. Res., 1985, 26, 1314.
• 3. Brunzell J. D., Schrott H. C., Motulsky A. G., et al.: Myocardial infraction in the familial forms of hypertriglyceridemia. Metabolism 1976, 25, 313.
• 4. Chen S. H., Habib G., Yang C. Y., et al.: Apolipoprotein B-48 is the product of a messenger RNA with an organspecific in-frame stop codon. Science 1987, 238, 363.
• 5. Collins D. R., Knott T.J., Pease R.J., et al.: Truncated variants of apolipoprotein B cause hypobetalipoproteinemia. Nucleic Acids Res., 1988, 16, 8361.
• 6. Cuching G. L., Gaubatz J. W., Burdick B. J., et al.: Localization and quantitation of apolipoprotein (a) and B in coronary artety bypass vein grafts resected at operation. Arteriosclerosis 1986, 6, 555a.
• 7. Dechelbaum R. J., Eisenberg S., Oschry Y., et al.: Abnormal high density lipoproteins of abetalipoproteinemia. Relerance to normal HDL metabolism. J. Lipid Res., 1982, 23, 1274.
• 8. Fless G. M., Zum Mallen M. E., Scanu A. M.: Physiochemical properties of apolipoprotein (a) and lipoprotein (a) derived from the dissociation of human plasma lipoprotein (a). J. Biol. Chem., 1986, 261, 8712.
• 9. Fless G. M., Zum Mallen M. E., Scanu A. M.: Heterogeneity of human plasma Lp(a). In: Workshop on lipoprotein heterogeneity. Ed: U. Lippel. Bethesda, National Institute of Health, MD, 1987, p. 141.
• 10. Gaubatz J. W., Cushing G. L., Morriseft J. D.: Quantitation, isolation and characterization of human Lp(a). Methods in Enzymology 1986, 129, 167.
• 11. Goodman D.S., Deckelbaum R. J., Palmer R. H., et al.: Cholesterol turnover and metabolism in two patients with abetalipoproteinemia. J. Lipid Res., 1983, 24, 1605.
• 12. Gurakar A., Hoeg J. M., Kostner G., et al.: Levels of lipoprotein Lp(a) decline with neomycin and niacin treatment. Atherosclerosis 1985, 57, 293.
• 13. Havel R. J., Kane J. P.: Introduction: structure and metabolism of plasma lipoproteins. In: The metabolism basis of inherited diseases. Ed: C. R. Screver. 1989, part 44A, p. 1129.
• 14. Hoff H. F., Beck G. J., Skibiński C. I., et al.: Serum Lp(a) level as a predictor of vein graft stenosis after coronary artery bypass surgery in patients. Circulation 1988, 77, 1238.
• 15. Hoefler G., Harnoncourt F., Paschke E., et al.: Lipoprotein Lp(a) a risk factor for myocardial infarction. Arteriosclerosis 1988, 8, 398.
• 16. Illingworth D. R., Connor W. E., Miller R. G.: Abetalipoproteinemia: Report of two cases and review of therapy. Arch. Neurol., 1984, 37, 659.
• 17. Illingworth D. R., Corbin D. K., Kemp E. D., et al.: Hormone changes during the menstmal cycle in abetalipoproteinemia. Reduced luteal phase progeserone in a patient with homozygous hypobetalipoproteinemia. Proc. Natl. Acad. Sci. USA 1982, 79, 6685.
• 18. Illingworth D. R., Kenny T. A., Orwoll E. S.: Adrenal function in heterozygons hypobetalipoproteinemia. J. Clin. Endocrinol. Metab., 1982, 54, 27.
• 19. Innerarity T. L.: Familial hypobetalipoproteinemia and familial defective apolipoprotein B-100: genetic disorders associated with apolipoprotein B. Current Opinion in Lipidology 1990, 1, 104.
• 20. Innerarity T. L., Weisgraber U. H., Arnold K. S., et al.: Familial defective apolipoprotein B-100: low density lipoprotein with abnormal receptor binding. Proc. Natl. Acad. Sci. USA 1987, 84, 6919.
• 21. Kane J. D., Hardman D. A., Paulus H. E.: Heterogenity of apolipoprotein B. Isolation of a new species from human chylomicron. Proc. Natl. Acad. Sci. USA 1980, 77, 2465.
• 22. Kane J. P., Havel R. J.: Disorders of the biogenesis and secretion of lipoproteins containing the B apolipoproteins. In: The Metabolic Basis of Inherited Diseases . Ed: C. R. Screver. 1989, part 448, p. 1139.
• 23. Kesaniemi Y. A., Grundy S. M.: Overproduction of low density lipoprotein associated with coronary heart disease. Arteriosclerosis 1983, 3, 40.
• 24. Kostner G. M., Varga M. B., Rotheneder M., et al.: Interaction of lipoprotein (a) with glycosaminoglycans. Possible mechanism for its atherogenecity. Arteriosclerosis 1986, 6, 522a.
• 25. Krauss R. N., Albers J. J., Brunzel J. D.: An apolipoprotein B enriched low density lipoprotein subspecies in familial combined hyperlipidemia. Clin. Res., 1983, 31, 503a.
• 26. Krempler F., Kostner G. M., Roscher A., et al.: Studies on the role of specific cell surface receptors in the removal of lipoprotein(a) in man. J. Clin. Invest., 1983, 72, 1431.
• 27. Kwiterovich P.O., White S., Forte T., et al.: Hyperapobetalipoproteinemia in a kindered with familial combined hyperlipidemia and familial hypercholesterolemia. Arteriosclerosis 1987, 7, 211.
• 28. Law S. W., Lachner R.J., Hospattanker A.V., et al.: Human apolipoprotein B-100: cloning, analysis of liver mRNA, and assigument of the gene to chromosome 2. Proc. Natl. Acad. Sci. USA 1985, 82, 8340.
• 29. Machley R. W., Weisgraber K. H., Innerarity T. L.: Interaction of plasma lipoproteins containing apolipoproteins B and E with heparin and cell surface receptors. Biochim. Biophys. Acta 1979, 575, 81.
• 30. Malloy M. J., Kane J. P., Hardman D. A., et al.: Normotriglyceridemic abetalipoproteinemia. Absence of the B-100 apolipoprotein. J. Clin. Invest., 1981, 67, 1441.
• 31. Nowicka G.: Lp(a) jako czynnik sprzyjający rozwojowi choroby wieńcowej serca. Żyw. Człow. Metab., 1990, 17, 70.
• 32. Rose H. G., Krauz P., Weinstock M., et al.: Inheritance of combined hyperlipoproteinemia. Evidence for a new lipoprotein phenotype. Amer. J. Med., 1973, 54, 148.
• 33. Roy C. C„ Levy E., Green P. H. R., et al.: Malabsorption, hypocholesterolemia, fat-filled enterocytes with increased intenstinal apoprotein B: Chylomicron retention disease. Gastroenterology 1987, 92, 390.
• 34. Scanu A. M.: Lipoprotein(a): genetically determined lipoprotein containing a glycoprotein of the plasminogen family. Seminars in Thrombosis and Hemostasis 1988, 14, 266.
• 35. Scanu A. M., Aggebeck L. P., Kruski A. W., et al.: A study of the abnormal lipoproteins in abetalipoproteinemia. J. Clin. Invest., 1974, 53, 440.
• 36. Soria L. F., Ludwig E. H., Clarke H. R. G., et al.: Association between a specific apolipoprotein B mutation and familial defective apolipoprotein B-100. Proc. Natl. Acad. Sci. USA 1989, 86, 587.
• 37. Talmud P. J., Lloyd J.U., Muller D. P. R., et al.: Genetic evidence from two families that the apolipoprotein B gene is not involved in abetalipoproteinemia. J. Clin. Invest., 1988, 82, 1803.
• 38. Teng B., Thompson G. R., Sniderman A. D., et al.: Composition and distritution of low density lipoprotein fractions in hyperapobetalipoproteinemia, normolipidemia and hypercholesterolemia. Proc. Natl. Acad. Sci. USA 1983, 80, 6662.
• 39. Uterman G., Menzel H.J., Kraft H.G., et al.: Lp(a) glycoprotein phenotypes. J. Clin. Invest., 1987, 80, 458.
• 40. Vessby G., Kostner G. H., Idhell H., et al.: Diverging effects of cholestyramine an apolipoprotein B and lipoprotein Lp(a). Atherosclerosis 1982, 44, 61.
• 41. Young S. G., Bertics S. J., Curtiss L. K., et al.: Characterization of an abnormal species of apolipoprotein B, apolipoprotein B-37, associated with familial hypobetalipoproteinemia. J. Clin. Invest. 1987, 79, 1831.
• 42. Young S.G., Bertics S. J., Curtiss L. K., et al.: Genetic analysis of a kindred with familial hypobetalipoproteinemia. Evidence for two separate gene defects: one associated with an abnormal apolipoprotein B species, apolipoprotein B-37, and a second associated with low plasma concentrations of apolipoprotein B-100. J. Clin. Invest., 1987, 79, 1842.
• 43. Zenker G., Rocltringer P., Bone G.: Lipoprotein Lp(a) as a strong indicator for cerebrovascular disease. Stroke 1986, 17, 942.